Loading…

Palivizumab Treatment of Respiratory Syncytial Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation

Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower...

Full description

Saved in:
Bibliographic Details
Published in:Clinical infectious diseases 2007-10, Vol.45 (8), p.1019-1024
Main Authors: de Fontbrune, Flore Sicre, Robin, Marie, Porcher, Raphael, Scieux, Catherine, de Latour, Régis Peffault, Ferry, Christèle, Rocha, Vanderson, Boudjedir, Karim, Devergie, Agnès, Bergeron, Anne, Gluckman, Eliane, Azoulay, Elie, Lapalu, Jordane, Socié, Gérard, Ribaud, Patricia
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Among 40 allogeneic stem cell transplant recipients who developed symptomatic respiratory syncytial virus infection, including 22 patients with lower respiratory tract infection, 19 received palivizumab (9 of whom had upper respiratory tract disease). Palivizumab did not prevent progression to lower respiratory infection and had no impact on the overall survival rate.
ISSN:1058-4838
1537-6591
DOI:10.1086/521912